Trophos
Trophos is a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.
Trophos' lead compound is TRO19622 / olesoxime,[1] which is now in a phase 3 trial (MitoTarget Project) in Europe in amyotrophic lateral sclerosis.[2] Olesoxime is a mitochondrial targeted compound, which will be established as first of a new class of therapeutic agents aimed at bringing significant therapeutic benefit to patients suffering from devastating neurological diseases.[3] [4]
Trophos recently also initiated the clinical development for TRO40303, a mitochondria pore modulator, which may become the first treatment to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen post myocardial infarction (MI).[5] Pre-clinical results suggested that TRO40303 can significantly reduce infarct size following cardiac ischemia-reperfusion. The first-in-human study will enroll healthy volunteers and will compare the safety and tolerability of a single dose of TRO40303 to placebo.
References
- ^ Bordet, Thierry; Buisson, Bruno; Michaud, Magali; Drouot, Cyrille; Galéa, Pascale; Delaage, Pierre; Akentieva, Natalia P.; Evers, Alex S. et al. (2007). "Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis". The Journal of pharmacology and experimental therapeutics 322 (2): 709–20. doi:10.1124/jpet.107.123000. PMID 17496168.
- ^ http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5002
- ^ "Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy". ClinicalTrialsFeeds.org. 05 February 2010. http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00876538. Retrieved 3 October 2010.
- ^ "Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)". ClinicalTrialsFeeds.org. May 2010. http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00868166. Retrieved 3 October 2010.
- ^ Schaller, Sophie; Paradis, Stéphanie; Ngoh, Gladys A.; Assaly, Rana; Buisson, Bruno; Drouot, Cyrille; Ostuni, Mariano A.; Lacapere, Jean-Jacques et al. (2010). "TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition". The Journal of pharmacology and experimental therapeutics 333 (3): 696–706. doi:10.1124/jpet.110.167486. PMID 20215409.
Further reading
- Rovini, Amandine; Carré, Manon; Bordet, Thierry; Pruss, Rebecca M.; Braguer, Diane (2010). "Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells". Biochemical pharmacology 80 (6): 884–94. doi:10.1016/j.bcp.2010.04.018. PMID 20417191.
- Xiao, Wen Hua; Zheng, Felix Y.; Bennett, Gary J.; Bordet, Thierry; Pruss, Rebecca M. (2009). "Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel". Pain 147 (1–3): 202–9. doi:10.1016/j.pain.2009.09.006. PMC 2787910. PMID 19833436. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2787910.
- Bordet, Thierry; Buisson, Bruno; Michaud, Magali; Abitbol, Jean-Louis; Marchand, Fabien; Grist, John; Andriambeloson, Emile; Malcangio, Marzia et al. (2008). "Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy". The Journal of pharmacology and experimental therapeutics 326 (2): 623–32. doi:10.1124/jpet.108.139410. PMID 18492948.
External links